ANIK:NSD-Anika Therapeutics Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 31.37

Change

+0.37 (+1.19)%

Market Cap

USD 0.46B

Volume

0.08M

Avg Analyst Target

USD 28.50 (-9.15%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ANIK Stock Forecast & Price:
Based on the Anika Therapeutics Inc stock forecasts from 2 analysts, the average analyst target price for Anika Therapeutics Inc is USD 28.50 over the next 12 months. Anika Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Anika Therapeutics Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Anika Therapeutics Inc’s stock price was USD 31.37. Anika Therapeutics Inc’s stock price has changed by -0.32% over the past week, +14.61% over the past month and -21.02% over the last year.

About Anika Therapeutics Inc (ANIK:NSD)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United St ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+4.76 (+4.04%)

USD45.54B 262.02 104.59
PODD Insulet Corporation

-1.55 (-0.51%)

USD21.17B 1,270.38 182.17
ABMD ABIOMED Inc

+2.96 (+0.78%)

USD17.04B 64.80 57.47
ALGN Align Technology Inc

+3.13 (+1.67%)

USD14.78B 28.00 16.65
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.64 (+0.97%)

USD9.78B 36.52 19.83
SWAV Shockwave Medical Inc

+5.31 (+2.27%)

USD8.41B 98.60 91.46
IART Integra LifeSciences Holdings

+0.89 (+1.60%)

USD4.57B 26.97 16.00
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
NARI Inari Medical Inc

+0.49 (+0.71%)

USD3.82B N/A -287.45

ETFs Containing ANIK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.45% 81% B- 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.45% 81% B- 60% D-
Trailing 12 Months  
Capital Gain -20.28% 73% C 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.28% 73% C 52% F
Trailing 5 Years  
Capital Gain -41.54% 51% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.54% 51% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -6.54% 44% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.54% 44% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 33.10% 71% C- 49% F
Risk Adjusted Return -19.76% 46% F 38% F
Market Capitalization 0.46B 71% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 78.21 26% F 13% F
Price/Book Ratio 1.62 62% D- 49% F
Price / Cash Flow Ratio 54.58 9% F 5% F
EV/EBITDA -62.41 96% A 92% A-
Management Effectiveness  
Return on Equity -5.48% 81% B- 53% F
Return on Invested Capital 1.54% 78% C+ 61% D-
Return on Assets -3.17% 77% C+ 45% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.37 16% F 11% F
Short Percent 9.02% 13% F 17% F
Beta 0.98 63% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector